Cetera Investment Advisers’s Esperion Therapeutics ESPR Stock Holding History

Cetera Investment Advisers’s Portfolio ESPR Stock Details ESPR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$73.4K	Sell	23,237 -8,444	-27%	-$23.6K	﹤0.01%	4718
2026 Q1	$86.8K	Sell	31,681 -122	-0.4%	-$386	﹤0.01%	4491
2025 Q4	$118K	Sell	31,803 -29,003	-48%	-$93.7K	﹤0.01%	4360
2025 Q3	$161K	Buy	60,806 +41,769	+219%	+$80.8K	﹤0.01%	4212
2025 Q2	$18.7K	Sell	19,037 -2,727	-13%	-$2.73K	﹤0.01%	4030
2025 Q1	$31.3K	Buy	21,764 +989	+5%	+$1.82K	﹤0.01%	3894
2024 Q4	$45.7K	Buy	20,775 +5,150	+33%	+$12K	﹤0.01%	3662
2024 Q3	$25.8K	Buy	15,625 +96	+0.6%	+$194	﹤0.01%	3640
2024 Q2	$34.5K	Buy	15,529 +9	+0.1%	+$21	﹤0.01%	3620
2024 Q1	$41.6K	Buy	+15,520	New	+$37.7K	﹤0.01%	3583

Other funds holding ESPR

GCL

Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Trium Capital London, United Kingdom $163M AUM 45.8% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

AQR Arbitrage Greenwich, Connecticut $7.02B AUM 31.58% 1-Year Est. Return

OBAM

ODDO BHF Asset Management Paris, France $2.16B AUM 43.32% 1-Year Est. Return

Cetera Investment Advisers's ESPR Position: Q2 2026 in Review

Cetera Investment Advisers reduced its Esperion Therapeutics (ESPR) stake by 27% in Q2 2026, selling an estimated $23.6K and leaving 23,237 shares worth $73.4K. The position accounts for ﹤0.01% of the portfolio, ranked #4718.

Cetera Investment Advisers first reported a position in ESPR in Q1 2024 and has held it in 10 quarters since. The position peaked at $161K in Q3 2025. 191 funds tracked by Wall St. Rank hold ESPR as of Q2 2026.

Cetera Investment Advisers held 23,237 shares of Esperion Therapeutics worth $73.4K as of Q2 2026.
Cetera Investment Advisers sold 8,444 Esperion Therapeutics shares in Q2 2026, an estimated $23.6K.
Esperion Therapeutics made up ﹤0.01% of Cetera Investment Advisers's portfolio in Q2 2026, its #4718 holding.
Cetera Investment Advisers first reported a position in Esperion Therapeutics in Q1 2024 and has held it in 10 quarters since.
Cetera Investment Advisers's Esperion Therapeutics position peaked at $161K in Q3 2025.
191 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q2 2026.

Based on Cetera Investment Advisers's 13F filing for Q2 2026, filed 12 Aug 2026.